Weight Loss Peptides: Semaglutide, Ozempic, Tirzepatide, Zepbound, Liraglutide, Exenatide, Dulaglutide

Seven molecules, forty years of science, and one class of drugs that is quietly rewriting how we treat obesity.

Last Updated April 18, 2026

7 GLP-1 receptor agonist peptides currently approved or widely used for weight or diabetes

22.5% Average body weight loss on tirzepatide 15 mg at 72 weeks (SURMOUNT-1)

1-2 min Half-life of natural GLP-1, the biological reason every drug in this class has an engineered half-life extender

1987 Year Dr. Joel Habener's team at Massachusetts General Hospital isolated GLP-1

🔑 Key Takeaways

All seven drugs covered on this page, semaglutide, ozempic, tirzepatide, zepbound, liraglutide, exenatide, and dulaglutide, are GLP-1 receptor agonists, peptide medicines that mimic a gut hormone to reduce appetite and improve blood glucose
Tirzepatide (Mounjaro, Zepbound) is the strongest, averaging roughly 22.5% body weight loss in SURMOUNT-1 at 72 weeks with the 15 mg dose, because it is a dual GIP plus GLP-1 agonist rather than GLP-1 alone
Semaglutide (Ozempic, Wegovy, Rybelsus) averaged about 15% body weight loss across the STEP trial program, with 86% of STEP 1 participants losing at least 5% and 50% losing at least 15%
Liraglutide (Victoza, Saxenda) averaged 5 to 10% weight loss in SCALE, with 63% of patients hitting the 5% threshold versus 27% on placebo
Exenatide (Byetta, Bydureon) and dulaglutide (Trulicity) were developed primarily for type 2 diabetes. Weight loss is modest (roughly 2 to 5 kg)
Gastrointestinal side effects hit 30 to 50% of patients in the first weeks of treatment but fade with slow titration. Rare serious effects include pancreatitis (0.1 to 0.2%) and gallbladder disease
Beyond weight loss, these peptides have documented cardiovascular protection (SELECT, LEADER, REWIND), NASH improvement, and early neuroprotection signals
The pipeline is moving fast: triple agonists (retatrutide), amylin combinations (CagriSema), and oral delivery (orforglipron, oral tirzepatide) are all in Phase 3

This page is a compound-by-compound reference covering all seven GLP-1 weight loss peptides available in 2026: what each does, how they differ, what the clinical trials show, how they compare to each other, side effects across the class, beyond-weight-loss benefits, and what is coming next. Every claim links to a peer-reviewed source or FDA record.

What Is GLP-1 and How Do These Peptides Work?

Glucagon-like peptide-1 is a gut hormone. L-cells in the intestine release it in response to a meal, and it does five things at once: enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, reduces appetite via hypothalamic and brainstem receptors, and shifts food preferences away from high-calorie options.

The catch is that natural GLP-1 is destroyed within 1 to 2 minutes by dipeptidyl peptidase-4 (DPP-4), which is why the body needs to keep producing it every time you eat. That 1-to-2-minute half-life is the reason every drug in this class exists: chemists figured out how to build GLP-1 analogs that evade DPP-4 and stay active for hours, days, or weeks (Nature Reviews Endocrinology, 2021).

Every drug on this page does the same core thing: binds and activates the GLP-1 receptor. Some also hit additional receptors (tirzepatide adds GIP, retatrutide adds both GIP and glucagon). The engineered half-life determines whether the drug is daily, weekly, or in the case of investigational compounds like MariTide, monthly.

How the 7 Peptides Compare

The short version.

Drug	Brand names	Receptor targets	Dose frequency	Avg weight loss	Approved for weight loss?
Semaglutide	Ozempic, Wegovy, Rybelsus	GLP-1	Weekly (injection) or daily (oral)	~15%	Wegovy: yes. Ozempic/Rybelsus: T2D only, off-label for weight
Tirzepatide	Mounjaro, Zepbound	GLP-1 + GIP	Weekly	~20-22.5%	Zepbound: yes. Mounjaro: T2D
Liraglutide	Victoza, Saxenda	GLP-1	Daily	~5-10%	Saxenda: yes. Victoza: T2D
Exenatide	Byetta, Bydureon	GLP-1	Twice daily or weekly	~2-5 kg	No (T2D only)
Dulaglutide	Trulicity	GLP-1	Weekly	~3-5%	No (T2D only)
Orforglipron	Foundayo	GLP-1	Daily (oral tablet)	~12%	Yes (approved late 2025)
Retatrutide	None yet	GLP-1 + GIP + Glucagon	Weekly	~24% (Phase 2)	Phase 3 trials ongoing

The per-compound breakdown below covers each in detail, with the trial references behind every number.

Semaglutide: The Molecule That Changed the Category

Semaglutide is the GLP-1 receptor agonist developed by Novo Nordisk. It launched as Ozempic in 2017 for type 2 diabetes, then as Wegovy in 2021 at higher doses specifically for chronic weight management, and as Rybelsus for oral diabetes treatment. The structural modifications, a fatty-acid side chain that binds albumin in the bloodstream, extend its plasma half-life to roughly 7 days, which is what makes weekly dosing possible (Lancet Diabetes & Endocrinology).

How it works. Semaglutide binds the GLP-1 receptor and reduces appetite through hypothalamic and brainstem signaling. It slows gastric emptying and influences food preference (Diabetes Obesity Metabolism). Most users describe the effect as "food noise" going quiet within the first week or two.

Trial data. The STEP 1 trial (NEJM 2021) showed an average 14.9% body weight reduction over 68 weeks on 2.4 mg weekly, with 86% of participants achieving at least 5% weight loss and 50% achieving at least 15%. STEP 2 tested the drug in adults with both obesity and type 2 diabetes. The SUSTAIN 7 head-to-head showed semaglutide outperformed dulaglutide for both glycemic and weight outcomes.

Safety. The most common adverse effects are gastrointestinal: nausea, vomiting, diarrhea, constipation. Serious but rare effects include pancreatitis and thyroid C-cell tumor warnings inherited from the class. Muscle loss during rapid weight reduction has also received attention, with concurrent resistance training and high protein intake now standard guidance.

For deeper coverage of the brand differences, see our Zepbound vs Wegovy comparison and the Ozempic side effects page.

Ozempic vs Wegovy vs Rybelsus: Same Molecule, Three Products

All three are semaglutide. The differences are dose, indication, and delivery.

Ozempic is the original brand, approved in 2017 for type 2 diabetes. Weekly injection. Dose goes up to 2.0 mg weekly.
Wegovy is the same molecule at higher dose (up to 2.4 mg weekly), specifically approved for chronic weight management in adults with BMI ≥30, or ≥27 with a weight-related condition. Also approved for adolescents 12 and older with obesity.
Rybelsus is oral semaglutide, approved for type 2 diabetes. Uses SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate), an absorption enhancer that protects semaglutide from stomach acid. Must be taken first thing in the morning on an empty stomach.

A high-dose oral Wegovy tablet (25 mg) received FDA approval in late 2025, making semaglutide available as both a weekly injection and a daily oral for weight loss.

Tirzepatide: The Dual GIP/GLP-1 Agonist

Tirzepatide is Eli Lilly's dual agonist, activating both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. Marketed as Mounjaro for type 2 diabetes (approved 2022) and Zepbound for chronic weight management (approved 2023). In December 2024, Zepbound also became the first drug ever approved for moderate to severe obstructive sleep apnea in adults with obesity.

How it works. The scientific surprise was that adding GIP receptor activation to a GLP-1 agonist produced synergistic benefit, despite earlier studies suggesting GIP promoted obesity on its own. Combined in a single molecule, the two receptors together amplify insulin secretion and enhance fat metabolism, and the GIP component appears to improve gastrointestinal tolerability compared to pure GLP-1 agonists (Molecular Metabolism) (JCI Insight).

Trial data. SURMOUNT-1 (NEJM 2022) reported an average 22.5% body weight loss at 72 weeks with the 15 mg dose. SURMOUNT-2 tested tirzepatide in people with obesity and type 2 diabetes, showing similar dramatic weight reduction. The SURPASS program across multiple trials (Diabetes Therapy) showed the largest HbA1c reduction of any injectable diabetes medication.

Safety. The gastrointestinal profile is similar to semaglutide but with slightly lower nausea and vomiting rates in head-to-head data. The same class warnings apply: pancreatitis, gallbladder disease, thyroid C-cell tumor warning for patients with MTC or MEN2 family history. See our tirzepatide side effects guide for the full profile.

Liraglutide: The First GLP-1 Approved for Weight Loss

Liraglutide was the original daily GLP-1 agonist. Novo Nordisk launched Victoza in 2010 for type 2 diabetes, then Saxenda in 2014 at higher dose for weight management, making it the first GLP-1 approved for obesity in the US. It has a 13-hour half-life, which is why it must be injected daily rather than weekly (J Clin Endocrinol Metab).

Trial data. The SCALE trial (NEJM 2015) tested liraglutide 3.0 mg in adults with obesity. 63% of participants achieved at least 5% weight loss versus 27% on placebo, with mean weight loss of 8%. The SCALE Diabetes sub-study confirmed similar effect in patients with type 2 diabetes. A critical review of liraglutide for weight management summarized the broader evidence.

Context in 2026. Liraglutide produces less weight loss than semaglutide or tirzepatide, and requires a daily injection rather than weekly. First generic liraglutide launched December 2024 through Hikma, which has brought cash prices down meaningfully. Still, most prescribers now pick semaglutide or tirzepatide over liraglutide unless insurance step therapy or specific clinical reasons (pediatric use, shorter half-life) dictate otherwise. The full detail is on our dedicated liraglutide page.

Exenatide: The Gila Monster Origin Story

Exenatide is a synthetic copy of exendin-4, a 39-amino-acid peptide originally isolated from the venom of the Gila monster (Heloderma suspectum). Dr. John Eng identified it at the Bronx VA Medical Center in 1992, and noticed it shared roughly 50% amino acid homology with human GLP-1, enough to activate the human GLP-1 receptor (Regulatory Peptides).

Formulations. Byetta (twice-daily injection, approved 2005) and Bydureon (once-weekly extended-release microsphere formulation, approved 2012) are the two commercial versions. Byetta has a short elimination half-life of 2.4 hours, which is why it is dosed twice daily before meals.

Trial data. Clinical trials in sulfonylurea-treated and metformin-plus-sulfonylurea patients showed modest weight loss of approximately 2 to 4 kg over 24 to 30 weeks (Diabetes Care 2004) (Diabetes Care 2005). The EXSCEL cardiovascular outcomes trial (NEJM 2017) was neutral on major cardiovascular events, which is part of why newer GLP-1s have largely replaced it.

Historical significance. Exenatide was the first GLP-1 receptor agonist ever approved by the FDA. A Phase 2 trial in Parkinson's disease (Lancet 2017) initially suggested possible neuroprotection, but the Phase 3 trial concluded in 2025 with negative results. For the full drug monograph, see our exenatide page.

Top Pick Semaglutide S-5 (5mg) GLP-1 agonist peptide for weight management. Same compound class as Ozempic/Wegovy, available as a compounded peptide. Exclusive 50% off — use code PEPTIDEDECK

Buy Semaglutide S-5 (5mg)

Dulaglutide: The IgG4 Fusion Protein

Dulaglutide (Trulicity) is Eli Lilly's once-weekly GLP-1 agonist. Approved in 2014 for type 2 diabetes, with cardiovascular risk reduction indication added in 2020. It is structurally unusual: two GLP-1(7-37) analog peptides covalently fused to an Fc fragment of a modified human IgG4 antibody. The antibody backbone recycles via neonatal Fc receptors, extending its half-life to several days and enabling weekly dosing (Diabetes Metabolism Research Reviews).

Trial data. AWARD-3 (Diabetes Care 2014) compared dulaglutide monotherapy against metformin. AWARD-6 (Lancet 2014) was the direct head-to-head with liraglutide. The REWIND cardiovascular outcomes trial (NEJM 2019), running over 5.4 years in 9,901 patients, showed a 12% reduction in major cardiovascular events, uniquely demonstrating benefit even in lower-risk T2D patients without established cardiovascular disease.

Context. Dulaglutide is not approved for weight loss, but typical users see 3 to 5% weight reduction as a side effect of the T2D treatment. It is the 63rd most prescribed medication in the US (2023, ~10 million prescriptions). Dose options range from 0.75 mg to 4.5 mg weekly, with the higher doses approved in 2020 based on the AWARD-11 trial. For the full drug monograph, see dulaglutide.

The Discovery of GLP-1 and the Birth of the Modern Class

The story starts in the 1960s with the discovery of the incretin effect: the observation that oral glucose produces a much larger insulin response than intravenous glucose of equivalent amount. That effect was attributed to gut hormones released in response to food, which researchers called incretins (Frontiers in Endocrinology, 2019).

In 1987, Dr. Joel Habener and colleagues at Massachusetts General Hospital isolated and characterized glucagon-like peptide-1, one of the two primary incretin hormones (early GLP-1 research). The Journal of Clinical Investigation later published Habener's own retrospective on the discovery and its development into clinical medicine.

The therapeutic challenge was that GLP-1 survives only 1 to 2 minutes in the bloodstream before DPP-4 degrades it (Hormone and Metabolic Research). Two research paths opened: DPP-4 inhibitors (to protect endogenous GLP-1) and engineered GLP-1 receptor agonists resistant to enzymatic degradation. The GLP-1 agonist path eventually produced every drug on this page.

The first approval came in 2005 for exenatide, based on the Gila monster peptide. Liraglutide followed in 2010 (Victoza) and 2014 (Saxenda). Dulaglutide arrived in 2014. Semaglutide launched in 2017 (Ozempic) and 2021 (Wegovy). Tirzepatide, the dual agonist, arrived in 2022 (Mounjaro) and 2023 (Zepbound). For a broader physiology overview, see the Glucagon-like peptide-1 reference and the state-of-the-art review in Molecular Metabolism.

Side Effects Across the Class

The side effect profile is remarkably consistent because the drugs all activate the same primary receptor.

Gastrointestinal effects (most common)

GI adverse events affect roughly 30 to 50% of patients, concentrated in the first weeks of treatment during dose escalation (Frontiers in Endocrinology disproportionality analysis):

Nausea: 15 to 40% depending on the drug. Worst in the first 4 weeks, fades with continued use.
Diarrhea: 10 to 20%. Typically mild and transient.
Vomiting: Variable, concentrated during titration.
Constipation: 5 to 15%. Some users alternate between diarrhea and constipation.

Management is straightforward: slow the titration (hold dose level an extra 4 weeks when needed), eat smaller more frequent meals, avoid fatty and spicy food, and hydrate. Most people adapt within 4 to 8 weeks of starting at a new dose. A broader clinical review is available in the Medical Advances in Body Weight, Nutrition, and Exercise (ScienceDirect) analysis.

"Ozempic face" and cosmetic concerns

A widely-discussed consequence of rapid weight loss is the facial volume loss commonly called "Ozempic face," a term coined by New York dermatologist Dr. Paul Jarrod Frank. This is not a direct drug effect but rather a predictable consequence of fast fat loss, seen with any rapid weight reduction including bariatric surgery (Dermatological Reviews). Mitigation strategies include slower weight loss, high protein intake, strength training, hydration, and topical skincare. See our dedicated Ozempic face page for the full treatment breakdown.

Rare but serious side effects

Pancreatitis: Estimated incidence 0.1 to 0.2%. Severe abdominal pain radiating to the back requires immediate discontinuation and evaluation.
Gallbladder disease: Rapid weight loss increases gallstone risk across the class. Right-upper-quadrant pain after fatty meals warrants imaging.
Thyroid C-cell tumors: A boxed warning exists for all GLP-1 agonists based on an early high-dose safety signal. Not confirmed in humans despite millions of patient-years of exposure.
Kidney injury: Severe vomiting and dehydration can trigger acute kidney injury. Aggressive hydration is essential.
Hypersensitivity reactions: Facial or throat swelling requires immediate discontinuation.

Contraindicated populations include patients with a personal or family history of medullary thyroid carcinoma or MEN2, history of pancreatitis, severe gastroparesis, pregnancy or active breastfeeding, and known hypersensitivity.

Beyond Weight Loss: Additional Health Benefits

The weight-loss effect is what made these drugs famous, but the cardiovascular and metabolic data may end up being the bigger story.

Cardiovascular protection

Semaglutide (SELECT): Reduced major cardiovascular events by 20% in adults with obesity and pre-existing cardiovascular disease without type 2 diabetes.
Liraglutide (LEADER): Reduced major cardiovascular events in patients with type 2 diabetes and established cardiovascular disease.
Dulaglutide (REWIND): 12% reduction in MACE over 5.4 years even in lower-risk T2D patients. This is a unique finding in the class.
Oral semaglutide (PIONEER-6): NEJM oral semaglutide CV outcomes demonstrated safety with trend toward benefit.

Liver (NAFLD / NASH)

Non-alcoholic fatty liver disease and its progressed form, NASH, frequently co-occur with obesity and type 2 diabetes. A placebo-controlled NEJM trial of subcutaneous semaglutide in NASH reported improvement in liver enzymes and histological endpoints in a substantial proportion of participants. Tirzepatide and survodutide are in ongoing MASH studies.

Neuroprotection (investigational)

Early research has explored GLP-1 agonism in Parkinson's and Alzheimer's disease. The Lancet's exenatide Parkinson's Phase 2 trial showed promise, but the larger Phase 3 trial concluded in 2025 without significant benefit. Semaglutide trials in Alzheimer's are underway.

Practical Administration

Injection technique

All injectable GLP-1 agonists are administered subcutaneously, into the fat layer just under the skin. The Best Practice in Injection Technique guideline documents the standard: rotate injection sites between the abdomen, front of thigh, and back of upper arm; use a fresh needle each time; avoid injecting into scar tissue, moles, or damaged skin; and dispose of used needles in an FDA-approved sharps container.

Repeated injection in the same site can cause lipohypertrophy, a benign thickening of subcutaneous tissue that impairs drug absorption (Cleveland Clinic). Site rotation is the single easiest way to prevent it.

Storage

Unopened pens or vials of all injectable GLP-1 agonists must be refrigerated at 2 to 8°C (36 to 46°F). After first use, most can be stored at room temperature up to 30°C (86°F) for 14 to 56 days depending on the specific drug. None should be frozen, and all should be protected from light and heat. Check the specific storage window for your drug on its prescribing information.

Titration schedules

Every drug in this class starts low and escalates slowly to reduce gastrointestinal side effects. Typical starting doses are 0.25 mg weekly for semaglutide, 2.5 mg weekly for tirzepatide, 0.6 mg daily for liraglutide, and 0.75 mg weekly for dulaglutide. Each drug has a recommended 4-week step-up schedule, but patients who experience strong side effects can hold a dose level for an extra 4 to 8 weeks without losing effect.

Diet and exercise

These medications work best alongside lifestyle intervention. A 2024 eClinicalMedicine trial tested weight-loss maintenance with exercise, GLP-1 agonist, or both combined. The combined intervention produced the best outcomes, consistent with the broader picture that medication plus lifestyle beats either alone. Current clinical guidance on lifestyle modification with second-generation anti-obesity medications recommends high protein intake, resistance training, and continuous glucose monitor-informed eating patterns during treatment.

The Future: Triple Agonists and Oral Delivery

The pipeline has moved fast and is still moving.

Triple agonists

Tirzepatide demonstrated that stacking receptors on one molecule produces synergistic effect. The next step is triple agonism. Retatrutide, Eli Lilly's GLP-1 + GIP + glucagon receptor agonist, is in Phase 3 TRIUMPH trials. Phase 2 data reported ~24.2% body weight loss at 48 weeks with the highest dose, and TRIUMPH-4 reported 28.7% at 68 weeks, the largest average weight loss recorded from any drug to date. The glucagon component is thought to increase metabolic rate and fat oxidation, on top of the appetite-suppression from GLP-1/GIP.

CagriSema (Novo Nordisk) combines semaglutide with cagrilintide (an amylin analog) and reported ~22.7% weight loss at 68 weeks in the REDEFINE-1 Phase 3 trial. Amylin works in parallel to GLP-1 to suppress appetite, and combining them produces stronger effect than semaglutide alone.

Survodutide (Boehringer Ingelheim) is a GLP-1/glucagon dual agonist in Phase 3 SYNCHRONIZE trials, with a parallel indication being developed for MASH liver disease.

Oral delivery

Most GLP-1 agonists require subcutaneous injection. Developing orally bioavailable peptides is hard because the stomach digests peptides. Novo Nordisk solved this for oral semaglutide (Rybelsus, Wegovy tablet) using SNAC, an absorption enhancer. Eli Lilly took a different path for orforglipron (Foundayo), a small-molecule non-peptide GLP-1 receptor agonist approved late 2025. Because orforglipron is not a peptide, it avoids the stomach-acid problem entirely, and can be taken any time of day with or without food.

Once-monthly injection

MariTide (maridebart cafraglutide) from Amgen is a GLP-1 agonist combined with a GIP receptor antagonist, dosed once monthly. Phase 2 showed roughly 20% weight loss at 52 weeks. If approved, it would be the first monthly GLP-1, removing a major adherence friction for long-term users.

Frequently Asked Questions

Which GLP-1 peptide produces the most weight loss?

Tirzepatide (Zepbound, Mounjaro) produces the most weight loss of any currently FDA-approved GLP-1 peptide, averaging 22.5% body weight loss at 72 weeks with the 15 mg dose in SURMOUNT-1. Semaglutide (Wegovy) averages about 15%. Liraglutide (Saxenda) averages 5 to 10%. Retatrutide, still in Phase 3, produced 24.2% in Phase 2 and 28.7% in TRIUMPH-4 at 68 weeks.

Are Ozempic, Wegovy, and Rybelsus the same drug?

All three are semaglutide, but at different doses, indications, and delivery methods. Ozempic (weekly injection, up to 2.0 mg) and Rybelsus (daily oral tablet) are FDA-approved for type 2 diabetes. Wegovy (weekly injection, up to 2.4 mg) is FDA-approved for chronic weight management. A high-dose oral Wegovy tablet (25 mg) received approval in late 2025.

Can I take these peptides if I don't have diabetes?

Yes, if you meet the weight-loss indication. Wegovy (semaglutide), Zepbound (tirzepatide), Saxenda (liraglutide), and Foundayo (orforglipron) are specifically approved for chronic weight management in adults without diabetes who have BMI 30 or higher, or BMI 27 or higher with a weight-related comorbidity. Ozempic, Mounjaro, Rybelsus, Trulicity, Byetta, and Bydureon are approved only for type 2 diabetes, and prescribing for weight loss alone would be off-label.

Do these peptides replace the need for diet and exercise?

No. Every clinical trial that established these drugs included dietary counseling and lifestyle intervention. Medication plus lifestyle consistently outperforms medication alone. High protein intake and resistance training are especially important because GLP-1 weight loss includes meaningful muscle loss without intervention.

Will I regain weight after stopping these peptides?

Yes, most patients do. Clinical trials show gradual regain of roughly two-thirds of lost weight within 1 to 2 years of discontinuation. The STEP 4 extension trial established this pattern for semaglutide. Patients who maintain lifestyle changes regain less. Gradual tapering may help minimize rebound. Current clinical consensus treats obesity as a chronic condition requiring ongoing medication in most cases.

What are the most common side effects?

Gastrointestinal effects dominate: nausea (15 to 40%), diarrhea (10 to 20%), constipation (5 to 15%), vomiting (6 to 24% depending on drug). Most resolve within 4 to 8 weeks at a stable dose. Serious but rare effects include pancreatitis (0.1 to 0.2%), gallbladder disease, and the class boxed warning for thyroid C-cell tumors in patients with MTC or MEN2 history.

Is it safe to combine peptides?

Two GLP-1 agonists should not be combined. Doing so provides no additional benefit and amplifies side effects. However, GLP-1 agonists can safely be combined with other classes: metformin is standard for T2D, SGLT2 inhibitors are frequent additions, and investigational combinations with amylin analogs (CagriSema) have shown benefit. Always coordinate changes with your prescriber.

How long until I see results?

Appetite suppression typically starts within the first week. Measurable weight loss begins within 2 to 4 weeks. A 5% weight loss threshold is usually reached between 3 and 6 months. Peak trial-average weight loss occurs around 60 to 72 weeks. Clinical guidelines recommend switching or stopping if you haven't achieved at least 5% weight loss after 3 to 6 months at the full therapeutic dose.

References

Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989-1002.
Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205-216.
Holst, J. J. (2007). The physiology of glucagon-like peptide 1. Physiological Reviews, 87(4), 1409-1439.
Shah, M., & Vella, A. (2014). Glucagon-like peptide 1 and appetite. Trends in Endocrinology and Metabolism, 24(2), 85-91.
Ahrén, B. (2004). GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Hormone and Metabolic Research, 36(11-12), 867-876.
Wikipedia contributors. Glucagon-like peptide-1.
Müller, T. D., et al. (2021). Glucagon-like peptide 1 (GLP-1) in the pathogenesis and treatment of obesity. Nature Reviews Endocrinology, 17(12), 745-760.
Drucker, D. J. (2021). Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists. Advances in Therapy, 38(6), 2821-2839.
van Can, J., et al. (2013). Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite, and energy metabolism in obese, non-diabetic adults. J Clin Endocrinol Metab.
Lund, A., Knop, F. K., & Vilsbøll, T. (2019). From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy. Frontiers in Endocrinology, 10, 260.
Holst, J. J., Ørskov, C., Nielsen, O. V., & Schwartz, T. W. (1987). Insulinotropin: Glucagon-like peptide I (7-37) co-encoded in the glucagon gene (early GLP-1 pharmacology paper).
Habener, J. F., & Stanojevic, V. (2017). Discovery, characterization, and clinical development of the glucagon-like peptides. Journal of Clinical Investigation, 127(12), 4217-4227.
Pratley, R. E., et al. (2018). Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7). Lancet Diabetes & Endocrinology.
Blundell, J., et al. (2017). Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obesity & Metabolism.
Davies, M., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet.
Lingvay, I., et al. (2019). Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8).
Ahrén, B., et al. (2017). Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes.
Coskun, T., et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism.
Willard, F. S., et al. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight, 5(17), e140532.
Min, T., & Bain, S. C. (2021). The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials. Diabetes Therapy.
Urva, S., et al. (2020). The novel dual GIP and GLP-1 receptor agonist tirzepatide transiently delays gastric emptying.
Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM.
Garvey, W. T., et al. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2).
Nauck, M. A., & Meier, J. J. (2016). Future glucose-lowering drugs for type 2 diabetes. Lancet Diabetes & Endocrinology.
Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE). NEJM, 373(1), 11-22.
Davies, M. J., et al. (2015). Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA.
Mehta, A., Marso, S. P., & Neeland, I. J. (2017). Liraglutide for weight management: a critical review of the evidence. Obesity Science & Practice.
Kolterman, O. G., et al. (2004). Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regulatory Peptides.
Buse, J. B., et al. (2004). Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care.
Kendall, D. M., et al. (2005). Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.
Glaesner, W., et al. (2010). Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein.
Umpierrez, G., et al. (2014). Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes (AWARD-3). Diabetes Care.
Dungan, K. M., et al. (2014). Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6). Lancet.
Nauck, M. A., et al. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism.
O'Neil, P. M., et al. (2018). Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity. Lancet.
Puhl, R. M., & Suh, Y. (2020). Weight stigma as a psychosocial contributor to obesity. American Psychologist.
NPR. (2024). How medications like Ozempic are revolutionizing the weight loss industry.
GBH News. (2023). Influencers and celebrities are using diabetes drug Ozempic to lose weight. What are the risks?
Liu, L., et al. (2022). Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system. Frontiers in Endocrinology.
Medical Advances in Body Weight, Nutrition, and Exercise (2024). Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks.
Humphrey, C. D., & Lawrence, A. C. (2024). Semaglutide "Ozempic" Face and Implications in Cosmetic Dermatology. Dermatological Reviews.
Forum for Injection Technique. Injection Technique Matters: Best Practice in Injection Technique for Insulin and GLP-1 Receptor Agonists.
Cleveland Clinic. Lipohypertrophy: What It Is and How to Prevent It.
Jensen, S. B. K., et al. (2024). Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined: a randomized controlled trial. eClinicalMedicine.
Rubino, D. M., et al. (2023). The Role of Lifestyle Modification With Second-Generation Anti-Obesity Medications. Current Obesity Reports.
Gerstein, H. C., et al. (2019). Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND). NEJM.
Newsome, P. N., et al. (2021). A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. NEJM.
Athauda, D., et al. (2017). Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. All medications discussed are prescription only and should be used under physician supervision. Individual results vary. Consult a licensed healthcare provider to determine which, if any, GLP-1 receptor agonist is appropriate for your health profile.